Ignite Creation Date:
2025-12-24 @ 7:15 PM
Ignite Modification Date:
2026-01-02 @ 9:17 AM
Study NCT ID:
NCT01001403
Status:
COMPLETED
Last Update Posted:
2010-05-11
First Post:
2009-10-23
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Effect of Nafamostat on Postreperfusion Syndrome (PRS)
Sponsor:
Seoul National University Hospital
Organization:
Study Overview
Official Title:
Effect of Nafamostat Mesilate on Hemodynamic Stability After Reperfusion of the Liver Graft
Status:
COMPLETED
Status Verified Date:
2010-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study intends to see the effect of nafamostat on the attenuation of postreperfusion syndrome (PRS) that frequently occurs during liver transplantation.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: